Reduce your patients’ need to travel for treatment
We understand the critically important role that Direct-to-Patient logistics services (DtP) play in maintaining treatment schedules. By reducing the need to travel for treatment, we make it easier for researchers to recruit and retain qualified patients for their studies, and for manufacturers to broaden the patient populations who can benefit from their innovations.
We also know about the complexity and collaboration required to deliver this service. Our extensive global network gives us the ability to navigate local regulations and restrictions, allowing us to flawlessly transition your trials to a DtP model during COVID-19.
E-book: Developing Patient-Centric Partnerships for the 21st Century
Improving patient experiences
The recruitment and retention of qualified patients can be challenging:
— 94% of patients don’t have access to clinical trials*
— 1 in 4 patients drop out before study completion*
— 78% of patients would find it helpful if IMP were delivered to their home**
However, moving some trial site activities into patients’ homes has been shown to increase recruitment by 60% or more, and typically maintains patient retention at over 95%*. That means Direct to Patient models can help bring your product to market faster, minimize disruptions to patients' lives and expand patient access to the best possible treatment options at home. There are also beneficial Direct to Patient applications for commercial drug home distribution programs, patient sample collections and returns.
*Medical Research Network
**International Society for Pharmaceutical Engineering
Delivering precision and professionalism
Medical Research Network (MRN)
Partnering for better clinical trials
Our collaboration offers an integrated clinical trial supply chain that improves the quality and accountability in the transport, storage and dispensing of products while maximising recruitment and retention in clinical trials.